Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-09-13
1991-12-24
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544284, C07D40306, A61K 31505
Patent
active
050753134
ABSTRACT:
Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
REFERENCES:
patent: 4276295 (1981-06-01), Ishikawa et al.
Varma et al., Indian J. Chem. 18B, 275-277 (1979).
Agarwal et al., Acta Pharm. Jugosl. 32, 37-44 (1982).
Agarwal et al., J. Chem. Soc. Pak. 6, 89-94 (1984).
Gupta et al., Indian J. Chem. 26B, 1197-1199 (1987).
Boltze et al., Arzneim. Forsch. 13, 688-701 (1963).
McCowan Jefferson R.
Thrasher K. Jeff
Yu Melvin J.
Eli Lilly and Company
Gupta Y. N.
Martens William C.
Shah Mukund J.
Whitaker Leroy
LandOfFree
3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical for does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical for, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical for will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-43662